Showing results (201-210 of 403) with videos related to

Sort By:
Pageof 41
American Journal of Human Genetics|June 5, 2001
The Silver syndrome variant of hereditary spastic paraplegia maps to chromosome 11q12-q14, with evidence for genetic heterogeneity within this subtypeH Patel, P E Hart, T T Warner, et al.
Clinical Endocrinology|May 3, 2006
GH replacement does not increase the risk of recurrence in patients with craniopharyngiomaNiki Karavitaki, Justin T Warner, Anne Marland, et al.
Practical Neurology|May 16, 2019
Training in neurology: lessons learntSamuel Shribman, Sian K Alexander, Angelika Zarkali, et al.
Current Oncology Reports|July 7, 2022
Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncologyJaidyn Muhandiramge, John R Zalcberg, G J van Londen, et al.
Journal of Neurology|September 17, 2004
A clinical, genetic and candidate gene study of Silver syndrome, a complicated form of hereditary spastic paraplegiaThomas T Warner, Heema Patel, Christos Proukakis, et al.
Annals of Epidemiology|September 25, 2021
Religious or spiritual coping, religious service attendance, and type 2 diabetes: A prospective study of women in the United StatesNicholas D Spence, Erica T Warner, Maryam S Farvid, et al.
Brain : a Journal of Neurology|October 12, 2019
Lower nucleus accumbens α-synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behavioursPedro Barbosa, Bimali Hapuarachchi, Atbin Djamshidian, et al.
Human Molecular Genetics|November 7, 2000
Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicityS J Tabrizi, M Orth, J M Wilkinson, et al.
Parkinsonism & Related Disorders|November 14, 2021
Reply to 'Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study.'Pedro Barbosa, Bimali Hapuarachchi, Atbin Djamshidian, et al.
Drug Discovery Today|August 4, 2023
Advancing novel therapies for neurodegeneration through an innovative model for industry-academia collaborations: A decade of the Eisai-UCL experiencePeter J Atkinson, Meera Swami, Nicola Ridgway, et al.
Pageof 41